Market Overview:
The global dengue testing market size reached US$ 555.5 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 761.6 Million by 2028, exhibiting a growth rate (CAGR) of 5.2% during 2023-2028.
Dengue, also known as breakbone fever, is a viral infection that spreads through the bite of an infected Aedes aegypti mosquito. It causes ache in the joints and muscles, high fever, abdominal pain, vomiting, difficulty in breathing, clammy and cold skin, headache, pain behind the eyes, fatigue, rashes, and mild bleeding in the nose and gums. It is diagnosed via dengue testing, which includes enzyme-linked immunosorbent assay (ELISA), RT-PCR, and dengue IgG/IgM rapid tests. Dengue testing is performed by medical professionals using a blood sample to identify the different serotypes of the dengue virus.
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
Dengue Testing Market Trends:
The growing cases of dengue on account of the rising global warming and breeding sites of mosquitos across the globe represents one of the major factors driving the market. Moreover, accurate and efficient diagnosis of dengue plays a pivotal role in clinical care. It assists in pathogenesis, clinical trials, outbreak control, academic research, vaccine development, surveillance activities, early detection of severe cases, and case confirmation and differential diagnosis with other infectious diseases. These benefits are positively influencing the demand for dengue testing around the world. Besides this, densely populated areas worldwide are more disease-prone due to low living conditions. This, along with poor sanitation and waste management techniques due to lack of public awareness, is stimulating the growth of the market. In addition, healthcare professionals are encouraging people to prevent dengue by self-protection and thermal fogging of insecticides. This, coupled with awareness campaigns organized by the government of several countries, is propelling the growth of the market. Other growth-inducing factors are rapid urbanization and technological advancements in the healthcare industry. Furthermore, key market players are extensively investing in research and development (R&D) activities to develop highly efficient and cost-effective dengue test kits.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global dengue testing market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on test type and end user.
Breakup by Test Type:
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
- ELISA-based Tests
- RT-PCR based Tests
- Dengue IgG/IgM Rapid Test
- Others
Breakup by End User:
- Hospitals
- Diagnostic Centers
- Others
Breakup by Region:
To get more information on the regional analysis of this market, Request Sample
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Abnova Corporation, CerTest Biotec S.L., DiaSorin S.p.A., F. Hoffmann-La Roche AG, InBios International Inc., NovaTec Immundiagnostica GmbH, OriGene Technologies Inc., PerkinElmer Inc., Quest Diagnostics Incorporated and Thermo Fisher Scientific Inc.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2022 |
Historical Period |
2017-2022 |
Forecast Period |
2023-2028 |
Units |
US$ Million |
Segment Coverage |
Test Type, End User, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Abbott Laboratories, Abnova Corporation, CerTest Biotec S.L., DiaSorin S.p.A., F. Hoffmann-La Roche AG, InBios International Inc., NovaTec Immundiagnostica GmbH, OriGene Technologies Inc., PerkinElmer Inc., Quest Diagnostics Incorporated and Thermo Fisher Scientific Inc. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global dengue testing market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global dengue testing market?
- What are the key regional markets?
- What is the breakup of the market based on the test type?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global dengue testing market and who are the key players?
- What is the degree of competition in the industry?